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of the patients affected remit within a year, non-remitting 
patients are at a high risk of transition to a fully syndro-
mal psychiatric disorder. The validity and clinical useful-
ness of MADD as a diagnostic category are under debate. 
It has not been included in the recently released DSM-5 
since the proposed diagnostic criteria turned out to be not 
sufficiently reliable. Moreover, reviewers have disputed the 
justification of MADD based on divergent results regarding 
its prevalence and course, diagnostic stability over time, 
and nosological inconsistencies between subthreshold and 
threshold presentations of anxiety and depressive disorders. 
We review the evidence in favor and against MADD and 
argue that it should be included into classification systems 
as a diagnostic category because it may enable patients to 
gain access to appropriate treatment early. This may help 
to reduce patients’ distress, prevent exacerbation to a more 
serious psychiatric disorder, and ultimately reduce the soci-
etal costs of this very common condition.
Keywords Mixed anxiety and depression · Subthreshold 
anxiety · Subthreshold depression · Classification · 
Psychiatric disorder
Background
It has been estimated that about 85 % of patients with 
depression also experience significant symptoms of anxi-
ety. Similarly, symptoms of depression occur in up to 90 % 
of patients with anxiety [1]. Co-morbid anxiety and depres-
sion may occur at any age, from childhood and adolescence 
[2] to old age [3]. They are more disabling, more resistant 
to treatment, have a greater risk of suicide, and are associ-
ated with more severe psychological, physical, social, and 
workplace impairment than either condition alone [e.g., 4].
Abstract According to ICD-10 criteria, mixed anxi-
ety and depressive disorder (MADD) is characterized by 
co-occurring, subsyndromal symptoms of anxiety and 
depression, severe enough to justify a psychiatric diagno-
sis, but neither of which are clearly predominant. MADD 
appears to be very common, particularly in primary care, 
although prevalence estimates vary, often depending on 
the diagnostic criteria applied. It has been associated with 
similarly pronounced distress, impairment of daily living 
skills, and reduced health-related quality of life as fully 
syndromal depression and anxiety. Although about half 
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By ‘depression’ and ‘anxiety,’ we refer to clinically rel-
evant disorders whose symptoms may cause profound suf-
fering and may interfere with essential activities of daily 
living. A clinical picture characterized by a combination 
of symptoms of anxiety and depression severe enough to 
justify a psychiatric diagnosis, neither of which are clearly 
predominant and which, when considered separately, do not 
meet the full diagnostic criteria of either syndromal anxiety 
(e.g., generalized anxiety disorder, GAD) or depressive dis-
order (e.g., major depressive disorder, MDD), may be diag-
nosed as mixed anxiety and depressive disorder (MADD) 
according to the criteria of the currently valid 10th revision 
of the International Statistical Classification of Diseases 
and Related Health Problems [ICD-10; 5].
Patients meeting the diagnostic criteria of MADD are 
particularly common in primary care [6, 7]. Although 
there is some variation in the estimated prevalence rates, 
researchers widely agree that MADD is among the most 
prevalent psychiatric disorders [e.g., 8, 9].
As will be argued below, patients suffering from sub-
syndromal psychiatric conditions, including MADD, have 
been shown to suffer from similarly pronounced distress, 
impairment of daily living skills, and reduced health-
related quality of life as individuals with a fully syndromal 
disorder [e.g., 7, 10]. Moreover, co-occurring depression 
and anxiety are associated with higher disability scores 
and co-morbid physical conditions than having anxiety or 
depression alone [e.g., 11].
Despite the undisputedly high prevalence of co-occur-
ring, subsyndromal symptoms of anxiety and depression in 
the community, the question of whether MADD is a scien-
tifically valid, clinically useful, and justified diagnosis in its 
own right is under scrutiny, and there is an ongoing debate 
as to whether it deserves a place in psychiatric nosology. In 
this article we make a case for retaining MADD as an inde-
pendent and valid diagnosis and present arguments why it 
should (continue to) be included into psychiatric classifica-
tion systems.
MADD in history
From the beginning of psychiatric nosology in the late 
nineteenth century until the 1970s, anxiety and depression 
were widely accepted in the non-psychoanalytic psychiat-
ric community as different manifestations of one affective 
spectrum disorder [12]. As a matter of fact, German psy-
chiatrist Emil Kraepelin, whose work in the late nineteenth 
century is recognized as seminal for modern classification 
systems of mental diseases, perceived anxiety to be a fun-
damental part of all psychiatric illnesses and therefore did 
not consider it to be an independent disorder [13]. The rise 
of psychopharmacology that started in the 1950s led to the 
development of drugs that had a relatively specific anti-
depressant (e.g., tricyclics) or anxiolytic effect (e.g., ben-
zodiazepines), and supported a dichotomization between 
depression and anxiety [12]. During the development of 
the 3rd edition of the Diagnostic and Statistical Manual of 
Mental Disorders [DSM-III; [14]], the drafting of the sec-
tions on depressive and anxiety disorders was assigned to 2 
different advisory committees, which contributed to the fact 
that anxiety and depression were included as completely 
different disorders in DSM-III, first released in 1980 [15].
In 1990 the World Health Organization (WHO) endorsed 
ICD-10 [5], which, unlike its predecessor ICD-9, accepted 
in 1978, included MADD in its section on anxiety disorders 
as a diagnostic category (F41.2; Table 1). The original defi-
nition was later complemented by a set of diagnostic guide-
lines for primary care [16] where patients with MADD are 
particularly common (Table 2).
Due to the large number of reports in the literature, and 
possibly also as a reaction to ICD-10, the DSM-IV Anxiety 
Disorders Workgroup proposed MADD for inclusion into 
DSM-IV [17]. A subsequently initiated field trial showed 
that MADD is seen frequently in clinical practice and 
involves significant distress, impairment, and increased risk 
of evolution to a more serious condition [18]. However, 
the DSM-IV task force decided to place the diagnosis in 
the research appendix, due to lack of information about its 
concurrent or predictive validity, interrater reliability, and 
prevalence in the general population [17], when the manual 
was finally published in 1994 [19].
The DSM-IV diagnostic research criteria for MADD 
are shown in Table 3. When DSM-5 was being developed, 
the Mood Disorders Workgroup again proposed to include 
MADD as an ‘official’ diagnostic category [17]. The cri-
teria proposed by the workgroup (Table 4) were, however, 
distinctly different from both those of the DSM-IV research 
appendix and the ICD-10 criteria, with the disadvantage 
that, for obvious reasons, there were no empirical data 
from studies in which these newly proposed criteria had 
ever been applied. The new criteria were evaluated in the 
Table 1  Mixed anxiety and depressive disorder in ICD-10 [5]
F41.2—Mixed anxiety and depressive disorder
Definition
This category should be used when symptoms of anxiety and 
depression are both present, but neither is clearly predominant, 
and neither type of symptom is present to the extent that justifies a 
diagnosis if considered separately. When both anxiety and depres-
sive symptoms are present and severe enough to justify individual 
diagnoses, both diagnoses should be recorded and this category 
should not be used
Inclusion
Anxiety depression (mild or not persistent)
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context of the DSM-5 field trials, where the diagnosis of 
MADD was assessed to be not sufficiently reliable [20, 21], 
which probably did not come as much of a surprise given 
the fact that there was practically no clinical experience in 
the application of the newly proposed criteria. Therefore, 
MADD was not included into the final version of DSM-5 
released in 2013 [22].
A survey performed jointly by the World Psychiatric 
Association (WPA) and the WHO among nearly 5000 psy-
chiatrists in 44 countries showed that MADD was the 4th 
most frequently used diagnostic category, but was among 
those with the lowest goodness of fit or accuracy and 
among the most difficult to use [23]. In view of the cur-
rently still ongoing revision of ICD it has therefore been 
suggested to maintain the category of MADD but to pro-
vide more explicit guidance for its diagnosis [24, 25].
According to the current draft version of ICD-11 [26], 
whose final version has now been scheduled for release in 
2017, the classification system will continue to include a 
diagnostic category for subsyndromal, co-morbid anxiety, 
and depression, which will, however, be moved from the 
anxiety disorders to the depressive disorders section and, 
accordingly, will be renamed ‘mixed depressive and anxi-
ety disorder.’ Moreover, in response to previous criticism 
Table 2  Mixed anxiety and depressive disorder—diagnostic guidelines for ICD-10 in primary care [16]
Presenting complaints
The patient presents with variety of symptoms of anxiety and depression
There may initially be one or more physical symptoms (e.g., fatigue, pain). Further enquiry will reveal depressed mood and/or anxiety
Diagnostic features
Low or sad mood
Loss of interest or pleasure
Prominent anxiety or worry
The following associated symptoms are frequently present: disturbed sleep, tremor, fatigue or loss of energy, palpitations, poor concentration, 
dizziness, disturbed appetite, suicidal thoughts or acts, dry mouth, loss of libido, tension, and restlessness
Differential diagnosis
If more severe symptoms of depression or anxiety are present, see management guidelines for Depression—F32 and Generalized anxiety—
F41.1
If somatic symptoms predominate, see Unexplained somatic symptoms—F45
If the patient has a history of manic episodes (excitement, elevated mood, rapid speech), see Bipolar disorder—F31
If heavy alcohol or drug use is present, see Alcohol use disorders—F10 and Drug use disorders—F11
Table 3  DSM-IV research criteria for mixed anxiety depressive disorder [19]
Persistent or recurrent dysphoric mood for at least 1 month
The dysphoric mood is accompanied by at least 1 month of four (or more) of the following symptoms
 Difficulty concentrating or mind going blank
 Sleep disturbance (difficulty falling asleep or staying asleep, or restless unsatisfying sleep)
 Fatigue or low energy
 Irritability
 Worry
 Being easily moved to tears
 Hypervigilance
 Anticipating the worst
 Hopelessness
 Low self-esteem or feelings of worthlessness
The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
The symptoms are not a result of the direct physiological effects of a substance or a general medical condition
All of the following
 Criteria have never been met for major depressive disorder, dysthymic disorder, panic disorder, or GAD
 Criteria are not currently met for any other anxiety or mood disorder (including an anxiety or mood disorder in partial remission)
 The symptoms are not better accounted for by any other mental disorder
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that the definition of MADD in ICD-10 was too vague 
[e.g., 7, 24, 27], a more elaborate set of criteria is being 
proposed (Table 5).
Anxiety and depression: two sides of the same 
coin?
There is both neurobiological and phenomenological evi-
dence that depression and anxiety may represent differ-
ent manifestations of a similar vulnerability that has been 
linked to a general ‘distress’ factor [7, 11, 28–30]. Already 
in 1991, Clark and Watson [31] proposed a tripartite model 
of affective disorders consisting of a general distress factor, 
physiological hyperarousal (specific to anxiety), and anhe-
donia (specific to depression).
In clinical as well as epidemiological studies, anxi-
ety and depression have consistently shown consider-
able symptom overlap [e.g., 32, 33]. Moreover, it has been 
observed that in a longitudinal perspective diagnostic con-
version between anxiety and depressive disorders is not 
unlikely to occur [34, 35]. It has therefore been suggested 
that the two conditions may be regarded as the extremes of 
one continuum [30] with a shared diathesis best described 
as non-specific ‘negative affect’ [36, 37].
The presence of psychiatric symptoms has been found 
to coincide with specific neurochemical variations that 
are independent of the clinical diagnosis [38–40]. The 
Table 4  Proposed criteria for DSM-5 mixed anxiety depression [from 17, Appendix II]
(1) The patient has three or four of the following symptoms for at least 2 weeks, one of which must be (a) or (b)
 (a) Depressed mood most of the day, almost every day, as indicated by either subjective report (e.g., feels sad or empty) or observation made by 
others (e.g., appears tearful)
 (b) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, almost every day
 (c) Significant weight loss when not dieting or weight gain (e.g., a change of more than 5 % of body weight in 1 month), or decrease or 
increase in appetite almost every day
 (d) Insomnia or hypersomnia almost every day
 (e) Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed 
down)
 (f) Fatigue or loss of energy nearly every day
 (g) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt 
about being sick)
 (h) Diminished ability to think or concentrate, or indecisiveness, almost every day (either by subjective account or as observed by others)
 (i) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan 
for committing suicide
(2) The symptoms in (1) are accompanied by two (or more) of the following symptoms of anxious distress, also lasting at least 2 weeks:
 (a) Irrational worry
 (b) Preoccupation with unpleasant worries
 (c) Having trouble relaxing
 (d) Motor tension
 (e) Fear that something awful would happen
(3) No other DSM diagnosis of anxiety or depression is present
Table 5  Proposed criteria for ICD-11 mixed depressive and anxiety disorder as of August 6, 2015 [26, foundation ID : http://id.who.int/icd/
entity/314468192 ]
7A73 Mixed depressive and anxiety disorder
Definition
Mixed depressive and anxiety disorder is characterized by symptoms of both anxiety and depression more days than not for a period of 2 weeks 
or more. Neither set of symptoms, considered separately, is sufficiently severe, numerous, or persistent to justify a diagnosis of a depressive 
episode, dysthymia, or an anxiety and fear-related disorder. Depressed mood or diminished interest in activities must be present accompanied 
by additional depressive symptoms as well as multiple symptoms of anxiety. The symptoms result in significant distress or significant impair-
ment in personal, family, social, educational, occupational, or other important areas of functioning. There have never been any prior manic, 
hypomanic, or mixed episodes, which would indicate the presence of a bipolar disorder
Inclusion
Anxiety depression (mild or not persistent)
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approach resembles the concept of target symptoms 
described by Freyhan already in 1979, according to 
which psychotropic drugs act on symptoms rather than 
on disorders [41] and may therefore be efficacious in 
different disorders that share common symptoms. The 
interpretation is supported by the observation that newer-
generation antidepressant drugs have been demonstrated 
to be efficacious in anxiety disorders as well. This is par-
ticularly true for selective serotonin reuptake inhibitors 
(SSRIs) whose efficacy in anxiety and depression has 
been linked to their agonistic action on the serotonin-1A 
receptor subtype (5-HT1A) [42–44], and the difference 
between their antidepressant and anxiolytic effect may 
depend on whether they act on pre-synaptic (anxiolytic) 
or post-synaptic (antidepressant) 5-HT1A receptors [45]. 
Consequently, SSRIs, that were originally developed as 
antidepressants [46], are now also recommended as first-
line treatment for anxiety disorders [e.g., 47], and there is 
also evidence that SSRIs are efficacious in MADD where 
studies have been performed for sertraline [48], fluvox-
amine [49], and citalopram [50]. Comparable results 
were also found for Silexan, a herbal active substance 
acting on the serotonin-1A receptor subtype [51], which 
was shown to be efficacious in anxiety disorders [52, 53] 
as well as in MADD [54].
Interestingly, investigations including cortical areas with 
high expression of serotonergic receptor subtypes provide 
further evidence for the argumentation that two extremes of 
one continuum are involved in the MADD mode of neu-
ronal activations and inhibition in the CNS [55, 56]. In 
addition, the orbito-frontal cortex (OFC) has a dense sero-
tonin innervation, and it is widely accepted that the inhibi-
tory control functions of the OFC are disrupted by seroto-
nin. A novel mode of investigating cortical dynamics [57], 
in correlation with transmitter receptor fingerprints [58] in 
GAD, depression and MADD, respectively, may help to 
develop more specific and effective strategies by accom-
plishing pharmacological studies for treating both sides 
of one coin: anxiety and depression, focused on the coin 
itself: MADD.
The hypothesis of two extremes switching in one contin-
uum, which is expressed in MADD, could be strengthened 
by neuroscientific findings of neuronal over-arousal in the 
anxious states and neuronal under-arousal in the depressive 
states, including impairment of intentional control of neu-
ral functioning [55] and self-focus in two segregated corti-
cal subareas of one functionally distinct area, the OFC [56, 
57]. Sensory cue inputs in depression and anxiety-related 
internal brain activities govern the firing of OFC neurons. 
Furthermore, the theta activity in the OFC is related to self-
referenced processing in depression and to aversive pro-
cessing in anxiety, reflecting two extremes in one neural 
continuum [57].
Independently of these findings, the genetic matching 
theory of MADD by Kendler and colleagues [59] provides 
evidence for the same genetic origin of anxiety and depres-
sion by shared genetic factors expressed in vulnerable 
patients (see [60], p. 13).
Clinical studies concerning the systematic analysis 
of both shared and separate specific symptoms based on 
genetic matchings [28, 59, 61] and on receptor fingerprints 
[58] in investigating anxiety and depression may help 
resolve the current controversial debate. This would foster 
the inclusion of MADD as an accepted epidemiological 
hypothesis in pharmacological treatment studies with spe-
cific designs in GAD, depression, and the combination of 
both (MADD), as a scientifically and clinically valid com-
mon entity [60–62].
Classification systems may thus benefit from an exten-
sion of the current, mainly phenomenology-based approach 
by the incorporation of reliably neurobiological findings, 
taking onto account the interrelationship between psycho-
logical, social, and cultural factors on the one hand and bio-
chemistry and physiology findings on the other.
Clinical evidence
Studies investigating the validity of the diagnosis of 
MADD according to the criteria of ICD-10 and the DSM-
IV research appendix have produced partly conflicting 
results.
Of 796 consecutive primary care clinic attendants with-
out known psychiatric illness interviewed by Stein and col-
leagues [63], 78 were further investigated systematically 
and 10 (12.8 %) met the ICD-10 or the authors’ own crite-
ria for MADD.
For the UK it has been estimated that co-occurring, sub-
threshold symptoms of anxiety and depression make up 
almost half of all psychological problems and are 4 times 
more common than depression alone [64].
In a longitudinal, naturalistic study of anxiety disorders 
in primary care reported by Weisberg et al. [65], patients 
screened positive for anxiety symptoms were also inter-
viewed for MADD, and only 4 out of 1634 participants 
(0.2 %) met the DSM-IV research criteria, with an adjusted 
probability of remission at 1 year after diagnosis of 80 %.
Using data of 1183 patients with various anxiety and 
depressive disorders from the WHO Collaborative Study on 
psychological problems in general health care [66], Barkow 
et al. [27] identified 85 cases with MADD according to 
ICD-10 criteria and found that only 1 of them still met the 
diagnostic criteria for MADD after 1 year. Whereas about 
half of the remaining patients remitted, about one quarter 
developed a syndromal anxiety and/or depressive disor-
der, while the remaining patients were diagnosed as having 
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some other ICD-10 psychiatric disorder. The authors con-
cluded that patients suffering from MADD are either only 
transiently affected or in a prodromal or residual state of a 
syndromal affective disorder. It should be noted, however, 
that the 1-year recovery rates reported by Barkow et al. 
[27] for patients with syndromal depressive or anxiety dis-
orders were comparable to those of patients with MADD 
although transition to another ICD-10 disorder was lower.
Similar observations were also published by Spijker 
et al. [67], based on health survey data from the Nether-
lands, who estimated a prevalence of MADD (defined on 
the basis of the DSM-IV research criteria) of 0.6 % in the 
general population and concluded that MADD is not a rel-
evant diagnosis in terms of prevalence and consequences 
when classified according to the currently proposed crite-
ria which exclude patients with previous relevant psycho-
pathology. By contrast, Usall and Marquez [68], using the 
DSM-IV research criteria, found MADD to be compara-
tively stable during 12-month follow-up.
Using taxometric methods, Schmidt et al. [69] analyzed 
data from a school-based sample of 706 adolescents in 
which they found a prevalence of MADD (according to the 
DSM-IV research criteria) around 13 %. Their results also 
support previous findings according to which MADD may 
be predictive of subsequent syndromal anxiety and depres-
sive disorders [e.g., 70].
In a survey of more than 21,000 patients who attended 
primary care for any reason, Balestrieri et al. [71] identified 
1.8 % of subjects with MADD, more than half of whom 
had no history of any anxiety or depression disorder. The 
results dispute the hypothesis that co-morbid, subsyndro-
mal anxiety and depression should be viewed as a state of 
partial remission of a previous syndromal disorder.
Based on representative population survey data of 8580 
respondents in Great Britain, Das Munshi et al. [7] found 
MADD (defined in accordance with ICD-10) to account for 
about half of the cases of common mental disorder, with 
a 1-month prevalence of 8.8 % and an impact on health-
related quality of life comparable to that of syndromal anx-
iety or depression. Using latent class analysis, the authors 
found considerable overlap between patients with MADD, 
those with depression and co-morbid anxiety, and those 
with anxiety and co-morbid depression, based on the pres-
ence of negative affect. The authors interpreted their results 
as challenging the notion of these conditions as having dis-
tinct phenomenologies.
Although Hettema et al. [72] fully implemented the 
DSM-IV and ICD-10 requirement that MADD could not 
be diagnosed if the subject had met prior lifetime criteria 
for a full mood or anxiety disorder, their latent class analy-
ses of data from more than 7500 participants of the popu-
lation-based Virginia Adult Twin Study of Psychiatric and 
Substance-Use Disorders [73] detected MADD prevalence 
rates of around 10 %. Comparing classification results of 
the 2 ‘waves’ of the survey performed about 17 months 
apart, they found that 47 % of the subjects classified as 
having MADD during the first wave were in remission 
during the second, 23 % had persistent MADD, and 30 % 
had developed syndromal anxiety or depressive disorder. 
Moreover, MADD was found to be significantly associated 
with childhood adversity, poor parenting, lifetime traumas, 
recent life events, high neuroticism, co-morbid substance-
use disorders, and familial aggregation. The authors con-
clude that MADD is a commonly occurring, identifiable, 
syndromal subtype that should be considered for inclusion 
in future nosological systems.
Similar rates of remission or progression in patients with 
ICD-10 compliant MADD were observed as well by Wal-
ters et al. [74] who also found that patients with MADD 
were twice as likely to have significant distress and persis-
tently lower mental health-related quality of life at 3-month 
follow-up than participants with no psychiatric diagnosis.
In a study performed in Germany, data from a random 
sample comprising 13.2 % of all 10,162,162 patients reg-
istered in the Ambulatory Health Care System in 2008 
were analyzed. Of all psychiatric diagnoses made by men-
tal health specialists, ICD-10 MADD was the most com-
monly diagnosed anxiety disorder (7.2 %), followed by 
panic disorder (4.4 %) and GAD (2.5 %) [75, 76]. How-
ever, the quality of these diagnoses was not scrutinized, so 
that it cannot be excluded that in many cases MADD was 
diagnosed although the patients fulfilled the full criteria for 
both syndromal depression and an anxiety disorder.
While the fact that a substantial number of individuals in 
the community, and notably of those seeking primary care, 
suffer from co-morbid symptoms of anxiety and depres-
sion is undisputed, the results regarding the prevalence of 
anxiety/depression co-morbidity meeting the criteria of 
MADD are discrepant and partly confusing. Since ICD-10 
and DSM-IV research criteria for MADD differ substan-
tially, it is not surprising that studies based on one set of 
criteria find prevalence rates and phenomenology differ-
ent from those using the other set. Moreover, some stud-
ies have excluded patients with a lifetime history of other 
anxiety or depressive disorders [67, 72], while others have 
not [e.g., 7, 69]. Nevertheless, there is also heterogeneity 
between some studies using the criteria from the same clas-
sification system.
Preskorn and Fast [77] have identified 2 main factors 
contributing to the difficulty to distinguish reliably between 
anxiety and depressive disorders, (a) the fact that diagnoses 
are mainly based on cross-sectional assessments and that 
the cross-sectional criteria for both disorders overlap con-
siderably, and (b) lack of focus on the longitudinal course 
of the patients’ complaints to which, according to Preskorn 
and Fast [77], particularly primary care physicians do not 
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devote enough time and are not adequately trained. While 
the authors conclude that a diagnostic category of MADD 
is not helpful and may even encourage cursory evaluation 
of patients rather than motivate physicians to reliably dis-
tinguish between anxiety and depression, their findings 
may also be interpreted in favor of a better operationaliza-
tion of the diagnostic criteria of MADD, particularly for 
use in primary care.
It should also be noted that the true prevalence of 
MADD is likely underestimated by community-based stud-
ies since affected individuals frequently present in primary 
care with somatic, rather than psychological, complaints 
[78].
Nosological issues
There is an ongoing debate as to whether a diagnostic cat-
egory of MADD is required for appropriately classifying 
patients with co-morbid, subthreshold anxiety and depres-
sion. While some researchers prefer a simultaneous classi-
fication of subthreshold anxiety disorder and subthreshold 
depression [e.g., 67, 79], others advocate a choice between 
the two [e.g., 77].
The proposal to code subthreshold anxiety and sub-
threshold depression separately implies the notion that the 
patient is suffering from 2 independent, readily distinguish-
able, and thus separately codable disorders. It should be 
noted, though, that throughout the history of psychiatric 
classification neurotic depression and anxiety were per-
ceived to be closely related concepts [13, 15] that were 
placed in 2 different classes of disorders only in DSM-III. 
As shown above, both phenomenological and neurobio-
logical evidence suggest that such a strict separation may 
not be appropriate as anxiety and depression may be bet-
ter explained as the extremes of a continuum characterized 
by non-specific distress or negative affect. Moreover, it is 
worth mentioning that current classification systems do 
not even include dedicated diagnostic categories for either 
subthreshold depression or anxiety. Instead, these presenta-
tions have to be coded in a residual, ‘catch all’ category like 
‘Depressive/anxiety disorder, unspecified’ (ICD-10 F32.9 
and F41.9) or ‘Other specified depressive/anxiety disorder’ 
(DSM-5), the combination of which is clearly not an appro-
priate, unequivocal characterization of the phenomenology 
observed in MADD.
As regards the second proposal, to classify patients with 
co-morbid, subthreshold depression and anxiety as either 
suffering from anxiety or depressive disorder, epidemiolog-
ical studies indicate that approximately half of the patients 
with MADD develop a syndromal psychiatric disorder 
within about a year [27, 72]. Therefore, it has been argued 
that if MADD is actually a prodromal stage of another 
psychiatric disorder, it should be classified in accordance 
with this disorder, not as an independent diagnostic concept 
[79]. While this argument is perfectly understandable from 
a research perspective, the question of whether a particu-
lar patient presenting with symptoms meeting the criteria 
of MADD will progress to some syndromal disorder, and 
to which disorder she/he is likely to progress, requires a 
longitudinal perspective that cannot always be obtained 
from the patient’s history and would rather necessitate a 
look into the future. In clinical practice, a ‘forced choice’ 
between anxiety (with co-morbid depression) and depres-
sion (with co-morbid anxiety) will likely lead to arbitrary 
decisions when both components are equally important and 
only cross-sectional and history information is available.
Batelaan et al. [79] have noted that there is a certain 
inconsistency in defining MADD as a diagnostic category 
for co-morbid, subthreshold anxiety and depression, while, 
at the same time, there is no comparable option when both 
components are equally important at the threshold level 
(e.g., a clinical presentation meeting the criteria of both 
MDD and GAD). Indeed, Tyler [29] has already pointed 
out that the discussion about the usefulness of MADD as 
a diagnostic category has mainly be focused on coexisting, 
subsyndromal presentations. He suggested that there should 
also be a diagnostic category for coexisting, syndromal 
GAD and MDD for which he proposed the term ‘cothy-
mia.’ Moreover, Hettema and colleagues have observed that 
symptom endorsement patterns differed between threshold 
and subthreshold anxiety and depressive disorders primar-
ily in a quantitative rather than qualitative manner, suggest-
ing MADD symptomatology may be better represented as a 
dimensional continuum [72]. Along the same line, a double 
threshold concept has been suggested which defines one 
threshold for mental disorder and a second (lower) thresh-
old for mental health [80]. The resulting between-thresh-
old zone of subthreshold mental illness could be useful in 
applying treatment according to disease severity, optimiz-
ing cost-effectiveness, and controlling the burden to the 
healthcare system [81].
In DSM-5, which does not include a diagnostic category 
for MADD, the specifier ‘with anxious distress’ has been 
added to depressive and bipolar disorders [22], and thus 
patients presenting with co-morbid, subsyndromal, equally 
important anxiety and depressive symptoms may be coded 
to be suffering from ‘Other specified depressive disor-
der with anxious distress.’ This suggests that the authors 
of DSM-5 may have perceived mixed symptoms of anxi-
ety and depression as depressive disorder with co-morbid 
anxiety. A study focusing on the consequences of illness on 
distress as well as on social, occupational, and psychologi-
cal functioning showed, however, that the symptom pro-
files of patients with MADD were easily distinguishable 
from those of patients with MDD but were similar to those 
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of patients with GAD from which they differed signifi-
cantly only in more severe depressed mood and less severe 
somatic symptoms of anxiety [82]. The authors concluded 
that in ICD-10 the placement of MADD in one group with 
other anxiety disorders (F41) is therefore appropriate.
Diagnosis determines treatment
Although anxiety and depression symptoms in MADD are 
subsyndromal by definition, they may nevertheless cause 
similar levels of distress and disability as those observed 
in patients with a syndromal diagnosis [e.g., 7, 10, 18, 83, 
84] and bear the risk of exacerbation to a syndromal disor-
der [e.g., 85–88] and thus warrant clinical recognition and 
require appropriate treatment [89]. Effective treatment of 
MADD is not just an end in itself, but a major preventive 
intervention that could potentially alter the future course of 
a patient’s psychiatric illness [90].
Epidemiological data and reports from clinical practice 
suggest, however, that patients suffering from subsyndro-
mal anxiety or depressive symptoms are often underrecog-
nized and, consequently, undertreated [64, 91, 92]. We 
would therefore like to emphasize the importance of an 
appropriate diagnostic category in order to guide appro-
priate treatment. One reason for the underrecognition of 
MADD may be the lack of a suitable diagnostic category 
in the ‘DSM world’ and the vagueness of, or difficulty in 
using, the diagnostic category provided in ICD-10 [23–25].
Particularly in primary care, patients suffering from 
anxiety and/or depression are likely to present with somatic 
complaints (e.g., muscle tension, headache, palpitations, 
tachycardia, shortness of breath, sexual dysfunction) rather 
than mental health symptoms [4, 78, 93] which may ‘mask’ 
an underlying affective disorder, including MADD. For 
example, in a study published by Kunik et al. [94], 26 % of 
the participants with chronic obstructive pulmonary disease 
also met the diagnostic criteria for both anxiety and depres-
sion, while another 35 % met the criteria for either anxiety 
or depression alone, but less than 40 % of those with anxi-
ety and/or depression were treated for this disorder. This 
may be another important factor contributing to the under-
recognition of MADD in primary care.
Since MADD is associated with significant disabil-
ity and impaired health-related quality of life, but in most 
cases is not a life-threatening condition, treatment should 
focus on the restoration of daily living skills and social 
functioning as well as on the prevention of an exacerba-
tion to a potentially more serious psychiatric disorder, and 
should include only very limited risk. Of note, the use of 
drugs whose bothersome and partly disabling adverse 
effects, such as anticholinergic reactions, headache, seda-
tion, gastrointestinal complaints, somnolence, weight gain, 
sexual dysfunction, or even anxiety and co-morbid insom-
nia, could aggravate the symptoms they were prescribed to 
treat, should be avoided. Co-morbid anxiety and depression 
have been shown to respond favorably to cognitive behav-
ioral therapy [95, 96]. However, psychotherapy is often no 
viable option, due to lack of places on treatment programs. 
Therefore drugs that provide symptom alleviation at mini-
mal risk are particularly important.
Up to now, there are only few randomized treatment 
studies for MADD. Since no drug has been licensed for 
the disorder, the affected patients have to be treated practi-
cally ‘off label.’ Therefore, guidelines cannot recommend 
evidence-based treatments for this common diagnostic 
entity. If MADD will remain in ICD-11, this might encour-
age researchers to do controlled trials in this disorder. At 
the moment, the US Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) require a full 
set of licensing studies for every single anxiety disorder, 
meaning that a drug licensed for panic disorder cannot 
automatically be used for GAD, etc. This is in contrast to 
the substantial diagnostic overlap among all anxiety dis-
orders. Moreover, there is no evidence for a differential 
indication of certain treatments for the different anxiety 
disorders. Instead, it has been shown that the effect sizes 
obtained with medications for the different anxiety disor-
ders are very similar [97]. If, in the future, FDA and EMA 
could be convinced that a new treatment could simply 
obtain a marketing authorization for ‘all anxiety disorders,’ 
including MADD, instead of separately for every disor-
der, this would result in less expenditure of time, money, 
and patients exposed to placebo, thus making it easier and 
more ethical to relieve anxiety symptoms in the affected 
patients.
Why MADD is an important diagnostic category 
in its own right
In addition to nosologically and scientifically motivated 
demurs about the validity and usefulness as a diagnos-
tic category, there are also concerns that an inclusion of 
MADD into classification systems could lead to a ‘medical-
ization’ of ‘minor, self-limiting symptoms of distress’ [74] 
and to stigmatization and undermining of coping strategies 
[17, 80]. However, by making a case for a diagnostic cat-
egory of MADD, we are not advocating to lower the bar for 
a diagnosis and thus to unnecessarily tag millions of mod-
erately ‘neurotic’ individuals with a psychiatric label. Our 
concern is with patients who suffer profoundly from dis-
tress and disability and whose symptoms, when considered 
in their entirety, clearly possess pathological significance. 
Denying such patients an appropriate diagnosis could well 
imply to withhold the required treatment as well.
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Studies prospectively investigating longitudinal data 
widely agree that approximately half of the patients diag-
nosed with MADD remit within about 1 year [27, 72, 74], 
only slightly more than identified for MDD or GAD [27]. 
Among the non-remitting patients a substantial proportion 
was found to progress to a syndromal depressive or anxi-
ety disorder or to another syndromal psychiatric diagnosis 
[27, 72]. While it has been argued that subthreshold symp-
toms of anxiety and depression may thus mainly be either 
self-limiting or a prodromal stage to a syndromal condi-
tion, not warranting a diagnostic entity in its own right [27, 
79], the same findings can also be interpreted as evidence 
that the development of a more severe form of affective 
disorder could likely be prevented in a substantial frac-
tion of patients by early recognition and appropriate treat-
ment of MADD, saving both patients’ suffering as well 
as healthcare and economic resources. Lamentably, fac-
tors allowing to reliably predict the course of MADD, and 
to differentiate between patients who are likely to remit 
spontaneously and those who are at a substantial risk of 
progression to a syndromal affective disorder, are yet to be 
identified [74].
Since individuals with subthreshold affective disorders 
may experience similar levels of distress and disability as 
patients with a syndromal diagnosis, patients with MADD 
also exhibit similar social and occupational dysfunction 
[90]. As shown for minor depression [98], subthreshold 
disorders like MADD are associated with similar indirect, 
non-medical costs (e.g., through production loss due to ill-
ness) as syndromal disorders. The recognition of MADD as 
a condition requiring treatment may thus result in increased 
costs for healthcare utilization, but may nevertheless be 
cost-effective from a societal perspective.
In day-to-day clinical practice, particularly in pri-
mary care, physicians diagnose and treat large numbers of 
patients who present with comparatively trivial, self-limit-
ing disorders. A good example is the common cold which, 
although it usually subsides within 2 weeks untreated, may 
cause profound, subjective suffering and has an enormous 
economic impact, mainly through loss of productivity [99, 
100]. Of course, treatment of the common cold appears 
to be perfectly justified both from a clinical and from an 
economic perspective, since (a) patients suffer, (b) there 
is a certain risk of much more severe and difficult to treat 
complications and exacerbations, and (c) secondary costs, 
resulting from disability, may be reduced by an accelera-
tion of recovery.
We have never heard of any criticism of common cold 
treatment founded in the conviction that a diagnosis of 
the disorder could lead to unjustified medicalization and 
stigmatization of millions of individuals who suffer from 
minor, self-limiting symptoms. This is because somatic 
disorders still appear to be perceived as something more 
‘acceptable’ and less stigmatizing than psychiatric dis-
orders, both in the general population and in the medical 
community. One thing that somatic and psychiatric disor-
ders have in common is that patients suffer. Since they do, 
physicians should attempt to assign a matching diagnosis 
and to initiate appropriate treatment. Rather than to lament 
the potential stigmatization through mental illness, and 
denying an appropriate diagnosis, the medical community 
should better work toward an end of the stigmatization of 
mental illness in general.
The inclusion of the diagnostic category of MADD into 
our classification systems will help patients to gain access 
to appropriate treatment early. At least, successful treat-
ment will reduce their suffering, even if the symptoms 
would otherwise have subsided after some time untreated. 
Moreover, there is also a fair chance that early treatment 
will prevent an exacerbation to a more serious condition. 
This is why we think that a diagnostic category of MADD 
is both justified and helpful in clinical practice.
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